TaiMed Biologics Inc (中裕新藥) expects quarterly sales to grow this year as a distribution partner expands prescription reimbursement coverage for Trogarzo, its newly approved HIV/AIDS drug.
Since gaining approval from the US Food and Drug Administration in March and commencing sales in the US on April 30, Trogarzo’s commercialization has been progressing at pace similar to that of previous new HIV/AIDS drug launches, TaiMed chief financial officer Jack Chen (陳怡成) yesterday told an investors’ conference in Taipei.
Montreal-based Theratechnologies Inc, TaiMed’s marketing and distribution partner in the US and Canada, is expected to finish negotiations with major public and private health insurance firms in the next four to six months, he said.
Based on precedents set by 13 other antiretroviral drugs, Trogarzo sales are expected to peak in its fourth year in that market, Chen said.
The US is the world’s biggest market for HIV/AIDS treatments, with about 1.4 million people infected, of which 450,000 to 650,000 are receiving treatment and an estimated 200,000 to 250,000 have developed multidrug resistance, he said.
TaiMed is looking to tap into the demand from an estimated 10,000 to 12,000 patients with multidrug resistance who are in need of alternative treatment options, such as Trogarzo, he added.
The company this year adopted the International Financial Reporting Standards 9 guidelines, marking a switch from the International Accounting Standards 18 it had been using until the end of last year, Chen said.
The change in accounting rules would affect the recognition of earnings from milestone payments and the valuation of 2.3 million Theratechnologies shares TaiMed received as part of its partnership with the Canadian firm, he said.
“We expect continued revisions to international accounting standards and are ready to make adjustments,” Chen said.
“It is better to track the company’s operating performance on a quarterly basis, as monthly sales could fluctuate widely due to time lag,” he said, adding that Trogarzo is produced by a manufacturing partner in China and product shipments to packaging and logistics centers in the US are based on anticipated demand.
The company’s NT$1 billion (US$33.4 million) plant in Hsinchu County’s Jhubei City (竹北) is expected to come online in 2020, which would help diversify production and cut reliance on WuXi Biologics (無錫生物製藥), a Chinese contract manufacturer, he said.
Inhouse manufacturing is expected to bring cost savings of 20 percent to 40 percent, he added.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by